Surrozen, Inc./DE Operating Income
Surrozen, Inc./DE (SRZN) reported Operating Income of -$10.37 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- Surrozen, Inc./DE operating income (loss) for the quarter ending 2026-06-30 was -$10.37M.
- Surrozen, Inc./DE operating income (loss) for the quarter ending 2026-03-31 was -$10.46M.
- Surrozen, Inc./DE operating income (loss) for the quarter ending 2025-12-31 was -$12.64M.
- Surrozen, Inc./DE operating income (loss) for the quarter ending 2025-09-30 was -$10.88M, a 983.52% decline year-over-year.
- Surrozen, Inc./DE operating income (loss) for fiscal 2025 was -$42.09M.
- Surrozen, Inc./DE operating income (loss) for fiscal 2024 was -$25.54M.
- Surrozen, Inc./DE operating income (loss) for fiscal 2023 was -$45.78M.
- Surrozen, Inc./DE operating income (loss) for fiscal 2022 was -$44.34M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 4 month | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.37M 10-Q · filed 2026-08-06 | -$20.83M 10-Q · filed 2026-08-06 | -$33.47M derived: sum of 3 quarters · filed 2026-08-06 | -$44.35M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | -$10.46M 10-Q · filed 2026-05-06 | -$23.09M derived: sum of 2 quarters · filed 2026-05-06 | -$33.98M derived: sum of 3 quarters · filed 2026-05-06 | -$43.00M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | -$12.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$23.52M derived: sum of 2 quarters · filed 2026-03-23 | -$32.54M derived: sum of 3 quarters · filed 2026-08-06 | -$42.09M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | -$10.88M 10-Q · filed 2025-11-07 | -$19.90M derived: sum of 2 quarters · filed 2026-08-06 | -$29.45M 10-Q · filed 2025-11-07 | -$38.05M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | -$9.02M 10-Q · filed 2026-08-06 | -$18.57M 10-Q · filed 2026-08-06 | -$27.16M derived: sum of 3 quarters · filed 2026-08-06 | -$25.93M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | -$9.55M 10-Q · filed 2026-05-06 | -$18.14M derived: sum of 2 quarters · filed 2026-05-06 | -$16.91M derived: sum of 3 quarters · filed 2026-05-06 | -$25.96M derived: sum of 4 quarters · filed 2026-05-06 | |||
| 2024-12-31 | -$8.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$7.36M derived: sum of 2 quarters · filed 2026-03-23 | -$16.41M derived: sum of 3 quarters · filed 2026-03-23 | -$25.54M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $1.23M 10-Q · filed 2025-11-07 | -$7.82M derived: sum of 2 quarters · filed 2025-11-07 | -$16.95M 10-Q · filed 2025-11-07 | -$26.67M derived: sum of 4 quarters · filed 2025-11-07 | |||
| 2024-06-30 | -$9.05M 10-Q · filed 2025-08-08 | -$18.18M 10-Q · filed 2025-08-08 | -$27.90M derived: sum of 3 quarters · filed 2025-08-08 | -$39.09M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | -$9.13M 10-Q · filed 2025-05-09 | -$18.85M derived: sum of 2 quarters · filed 2025-05-09 | -$30.04M derived: sum of 3 quarters · filed 2025-05-09 | -$40.32M derived: sum of 4 quarters · filed 2025-05-09 | |||
| 2023-12-31 | -$9.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$20.91M derived: sum of 2 quarters · filed 2025-03-31 | -$31.19M derived: sum of 3 quarters · filed 2025-03-31 | -$45.78M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | -$11.19M 10-Q · filed 2024-11-06 | -$21.46M derived: sum of 2 quarters · filed 2024-11-06 | -$36.06M 10-Q · filed 2024-11-06 | -$38.23M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | -$10.28M 10-Q · filed 2024-08-12 | -$24.87M 10-Q · filed 2024-08-12 | -$27.04M derived: sum of 3 quarters · filed 2024-08-12 | -$40.64M derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | -$14.59M 10-Q · filed 2024-05-08 | -$16.76M derived: sum of 2 quarters · filed 2024-05-08 | -$30.37M derived: sum of 3 quarters · filed 2024-05-08 | -$44.44M derived: sum of 4 quarters · filed 2024-05-08 | |||
| 2022-12-31 | -$2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$15.77M derived: sum of 2 quarters · filed 2024-04-10 | -$29.85M derived: sum of 3 quarters · filed 2024-04-10 | -$44.34M 10-K · filed 2024-04-10 | |||
| 2022-09-30 | -$13.61M 10-Q · filed 2023-11-08 | -$27.68M derived: sum of 2 quarters · filed 2023-11-08 | -$42.17M 10-Q · filed 2023-11-08 | -$57.16M derived: sum of 4 quarters · filed 2023-11-08 | |||
| 2022-06-30 | -$14.07M 10-Q · filed 2023-08-09 | -$28.57M 10-Q · filed 2023-08-09 | -$43.56M derived: sum of 3 quarters · filed 2023-08-09 | -$57.27M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | -$14.49M 10-Q · filed 2023-05-10 | -$29.49M derived: sum of 2 quarters · filed 2023-05-10 | -$43.19M derived: sum of 3 quarters · filed 2023-05-10 | -$55.85M derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2021-12-31 | -$14.99M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$28.70M derived: sum of 2 quarters · filed 2023-03-31 | -$41.36M derived: sum of 3 quarters · filed 2023-03-31 | -$54.39M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$13.71M 10-Q · filed 2022-11-14 | -$26.36M derived: sum of 2 quarters · filed 2022-11-14 | -$39.40M 10-Q · filed 2022-11-14 | -$50.23M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$12.66M 10-Q · filed 2022-08-11 | -$1.05M 10-Q · filed 2021-08-09 | -$25.69M 10-Q · filed 2022-08-11 | -$2.11M 10-Q · filed 2021-08-09 | -$36.53M derived: sum of 3 quarters · filed 2022-08-11 | -$45.17M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$13.03M 10-Q · filed 2022-05-11 | -$1.07M 10-Q · filed 2021-05-24 | -$23.87M derived: sum of 2 quarters · filed 2022-05-11 | -$32.51M derived: sum of 3 quarters · filed 2022-05-11 | |||
| 2020-12-31 | -$10.84M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$438.76K 10-K/A · filed 2021-05-14 | -$19.48M derived: sum of 2 quarters · filed 2022-03-28 | -$32.81M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | -$8.64M 10-Q · filed 2021-11-15 | -$21.97M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |